Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction-Reference-Cited by-同舟云学术

Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction

Published:2020-05 Issue:5 Volume:1864 Page:129543
ISSN:0304-4165
Container-title:Biochimica et Biophysica Acta (BBA) - General Subjects
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - General Subjects

Author:

Lafferty Ryan A.,Tanday Neil,Flatt Peter R.,Irwin Nigel

Funder

Invest Northern Ireland

University of Ulster

Publisher

Elsevier BV

Subject

Molecular Biology,Biochemistry,Biophysics

Reference44 articles.

1. Emerging therapeutic potential for peptide YY for obesity-diabetes;Lafferty;Peptides,2018

2. PYY(1–36) peptides from phylogenetically ancient fish targeting mammalian NPY1 receptors demonstrate potent effects on pancreatic beta-cell function, growth and survival;Lafferty;Diabetes Obes. Metab.,2019

3. Peptide yy: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse;Bottcher;Pancreas,1989

4. Islet distribution of peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival;Khan;Mol. Cell. Endocrinol.,2016

5. PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following roux-en-Y gastric bypass surgery;Ramracheya;Cell Rep.,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes;Molecules4Life;2023-12-07

2. Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes;Peptides;2023-02

3. Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists;Diabetes, Obesity and Metabolism;2022-08-11

4. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice;Biochimie;2022-08

5. Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineage;Peptides;2022-06